Managed Healthcare Executive February 24, 2024
Denise Myshko

The FDA has removed the approval of Pepaxto in multiple myeloma. The agency approved Amtagvi, the first TIL therapy for a solid tumor, as well a new biweekly dosing of Tecvayli for multiple myeloma. The agency has set actions for several products, including a first-in-class lung cancer therapy, a bispecific antibody for advanced multiple myeloma, and another for Dupixent for COPD

FDA Withdraws Approval of Pepaxto in Multiple Myeloma

The FDA has withdrawn the approval of Oncopeptides’ Pepaxto (melphalan flufenamide), which was approved for use in combination with dexamethasone to treat certain patients with multiple myeloma. The final decision was issued by FDA’s Center for Biologics Evaluation and Research Director Peter Marks, M.D., Ph.D.

Regulators indicated that the confirmatory study...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
Related Articles:
To Give Rare Disease Patients Hope, the FDA Must Re-Focus its Efforts
Opinion: Adding psychotherapy to drug therapy works, but the FDA may not be able to handle it
FDA clears heart rhythm AI that turns smartphones into medical devices
Why Millions Are Trying FDA-Authorized Alternatives to Big Pharma’s Weight Loss Drugs
Accelerated Approval Pathway for Cancer Drugs: Does It Work?

Share This Article